On Aug. 9, 2022, Moderna announced an amendment to its agreement with the European Commission to convert contractually agreed doses of Moderna’s COVID-19 vaccine (Spikevax, mRNA-1273) to the Company’s Omicron-containing bivalent vaccines for supply in 2022, pending regulatory approval. In addition, the EC has agreed to purchase an additional 15 million doses of Omicron-containing vaccine booster candidates from Moderna.